Disc Medicine had its Relative Strength (RS) Rating upgraded from 67 to 74 Tuesday — a welcome improvement, but still shy of the 80 or better score you prefer to see.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's unique rating tracks price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners tend to have an RS Rating north of 80 in the early stages of their moves. See if Disc Medicine can continue to rebound and hit that benchmark.
While it's not currently an ideal time to jump in, see if the stock goes on to form a chart pattern and break out.
Disc Medicine posted 0% earnings growth in the latest quarterly report, while sales growth came in at 0%.
Disc Medicine holds the No. 130 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Anbio Biotechnology are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
